Cancer Stem Cell News Volume 14.10 | Jun 04 2025

    0
    2







    2025-06-04 | CSCN 14.10


    Cancer Stem Cell News by STEMCELL Technologies
    Vol. 14.10 – 4 June, 2025
    TOP STORY

    Mn-Coordination Driven Glutamine and Cancer Stemness Dual-Tailored Nano-Herb for High-Efficiency Activation of Dendritic Cells

    Scientists developed a manganese-coordination driven glutamine and cancer stemness dual-tailored nano-herb for high-efficiency activation of dendritic cells.
    [Biomaterials]

    Abstract
    PUBLICATIONSListed by the impact factor of the journal

    SMYD3 Activates Fatty Acid β-Oxidation to Promote Self-Renewal of Leukemia Stem Cells

    Researchers validated the critical role of the histone methyltransferase SET and MYND domain-containing 3 (SMYD3) in the maintenance of leukemia stem cells in chronic myeloid leukemia.
    [Cancer Research]

    Abstract

    CDX1 and CDX2 Suppress Colon Cancer Stemness by Inhibiting β-Catenin-Facilitated Formation of Pol II-DSIF-PAF1C Complex

    Investigators showed that complete loss of Cdx1 or concurrent loss of Cdx1/2 increase the stemness and malignancy of intestinal tumors.
    [Cell Death & Disease]

    Full Article

    DAZAP1 Maintains Gastric Cancer Stemness by Inducing Mitophagy

    Scientists investigated DAZ-associated protein 1’s (DAZAP1’s) impact on gastric cancer stemness and its mechanisms. DAZAP1 promotes tumor progression in gastric cancer stem cells, as shown by sphere formation assays and stemness marker analysis.
    [JCI Insight]

    Full Article

    The Cancer-Associated Fibroblast Facilitates YAP Liquid-Liquid Phase Separation to Promote Cancer Cell Stemness in HCC

    Investigators identified a novel long non-coding RNA NEAT1 in cancer-associated fibroblast-derived extracellular vesicles that plays a critical role in the induction of CSCs and hepatocellular carcinoma tumorigenesis.
    [Cell Communication and Signaling]

    Full Article

    Sohlh1 Modulates the Stemness and Differentiation of Glioma Stem-Like Cells by Inactivation of Wnt/β-Catenin Signaling Pathway via SFRP1

    Researchers demonstrated that Sohlh1 functions through the SFRP1/Wnt/β-catenin signaling pathway and leads to the consequent suppression of glioma stem-like cells (GSLC) stemness and the promotion of GSLC differentiation in vitro and in vivo.
    [Journal of Cellular and Molecular Medicine]

    Full Article

    Targeting of the IL-33/Wnt Axis Restricts Breast Cancer Stemness and Metastasis

    IL-33 overexpression enhances proliferation, migration, and CSC marker expression in 4T1 and MDA-MB-231 cells, whereas ST2 knockdown via CRISPR or adeno-associated virus attenuates tumor growth and metastasis in vivo, reducing CSC frequency.
    [Scientific Reports]

    Full Article

    Cinobufagin Inhibits Hepatocellular Carcinoma EMT-Like Stemness via VEGF/VEGFR2 Autocrine Signaling

    Researchers explored the role of the vascular endothelial growth factor (VEGF) a/VEGF receptor 2 (VEGFR2) autocrine pathway in cinobufagin-induced inhibition of hepatocellular carcinoma metastasis.
    [Discover Oncology]

    Full Article

    Combined Analysis of Somatic Mutations and Gene Expression Reveals Nuclear Speckles-Associated Enhanced Stemness in Gingivobuccal Carcinoma under DNA Damage Response

    An RNA-sequencing data-based combined analysis of somatic mutations and gene expression was performed to explore the role of CSCs in disease progression using the novel Indian-origin Gingivobuccal oral squamous cell carcinoma cell line ‘IIOC019’ from a patient with tobacco-chewing habit.
    [Computational Biology and Chemistry]

    AbstractGraphical Abstract
    Your Online Resource for Cell Visualization. View StainsFile.
    REVIEWS

    Exosomes in Bridging Macrophage-Fibroblast Polarity and Cancer Stemness

    CSC-derived exosomal transforming growth factor-β is a key driver of cancer-associated fibroblasts and type 2 macrophage polarization, with the latter mediated through activation of signal transducer and activator of transcription 3.
    [Medical Oncology]

    Abstract
    INDUSTRY AND POLICY NEWS

    Avenzo Therapeutics Initiates Phase I/II Clinical Study of AVZO-1418, a Potential Best-in-Class, Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate

    Avenzo Therapeutics, Inc.announced initiation of a Phase I/II clinical study of its potential best-in-class EGFR/HER3 bispecific antibody-drug conjugate, AVZO-1418, in patients with advanced solid tumors.
    [Avenzo Therapeutics, Inc.]

    Press Release
    FEATURED EVENT

    ESMO Gastrointestinal Cancers Congress 2025

    July 2-5, 2025
    Barcelona, Spain

    > See All Events

    JOB OPPORTUNITIES

    Associate/Assistant Professor – Biomedical Sciences

    University of Macau – Macau, China

    Postdoctoral Fellow – Neurodegeneration & Cancer Biology

    University of Pennsylvania – Philadelphia, Pennsylvania, United States

    Assistant/Associate/Full Professor – Cancer Biology

    Indiana University – Bloomington, Indiana, United States

    Postdoctoral Fellow – Stem Cell and Cancer Research

    Erasmus University Medical Center – Rottterdam, Netherland

    Postdoctoral Fellow – Cancer and Stem Cell Biology

    City of Hope – Monrovia, California, United States
    UR bale>

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2